Global Hedgehog Pathway Inhibitors Market is segmented By Product Type (Vismodegib, Glasdegib, Sonidegib, Itraconazole, Oxysterol, Saridegib), By Pathway Type (Canonical Hedgehog Signaling, Non-Canonical Hedgehog Signaling), By Application (Basal Cell Carcinoma, Acute Myeloid Leukemia, Medulloblastoma, Gorlin Syndrome, Others), By Route of Administration (Oral, Topical), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Hedgehog Pathway Inhibitors Market Overview
The Global Hedgehog pathway inhibitors Market is estimated to reach at a high CAGR during the forecast period (2024-2031).
Hedgehog pathway inhibitors are relatively a new class of therapeutic agents that target the proteins involved in the regulation of the hedgehog pathway.
Hedgehog Pathway Inhibitors Market Summary
|
Metrics |
Details |
|
Market CAGR |
High |
|
Segments Covered |
By Product Type, By Pathway Type, By Application, By Route of Administration, By Distribution Channel, and By Region |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
|
Fastest Growing Region |
Asia Pacific |
|
Largest Market Share |
North America |
To Know More Insights - Download Sample
Hedgehog Pathway Inhibitors Market Growth Trends
The hedgehog pathway inhibitors market growth is driven by the rising prevalence of cancer, hereditary factors, new product launches, rising demand for painless or minimally invasive treatment, and increased resistance to existing therapies.
The rising prevalence of cancer, is expected to drive the growth in the forecast period
The rising prevalence of cancer is boosting the Hedgehog pathway inhibitors market. For instance, according to the American Cancer Society, approximately 1,735,350 new cancer cases were registered for 2018 in the US. Nearly 9,500 people in the US are a target of skin cancer or Basal Cell Carcinoma. Estimation says that non-melanoma carcinoma, including basal cell carcinoma and squamous cell carcinoma, affects more than 3 million globally per year. According to the American Brain Tumor Association, approximately 25% of patients in the US are suffering from medulloblastoma due to the uncontrolled Sonic Hedgehog (SHH) pathway. Individuals with medulloblastoma showed a high cholesterol level when the combination of statin (simvastatin) and Hedgehog pathway inhibitor (vismodegib) was administered to the cohort. The combination therapeutics produces synergistic activity of the inhibitors.
The rise in the risk factors associated with basal cell carcinoma (BCC) and acute myeloid leukemia (AML), is expected to drive the growth in the forecast period
The rise in the risk factors associated with basal cell carcinoma (BCC) and acute myeloid leukemia (AML) is projected to fuel the global hedgehog pathway inhibitors market. The risk factors associated with developing basal cell carcinoma and acute myeloid leukemia include chronic infections, history of skin cancer, exposure to certain chemicals, skin inflammations, smoking, and exposure to UV rays. These risk factors raise the prevalence and incidence of basal cell carcinoma and acute myeloid leukemia. This, in turn, is anticipated to boost the growth of the global hedgehog pathway inhibitors market during the forecast period.
Side effects associated with hedgehog pathway inhibitors is likely to hamper the market growth
The most frequently encountered side effects were muscle spasms, alopecia, dysgeusia, weight loss, fatigue, nausea, anorexia, and diarrhea are likely to hamper the market growth.
COVID-19 Impact Analysis on Hedgehog Pathway Inhibitors Market
The COVID-19 pandemic has led to the halt of several industrial processes causing unprecedented economic loss. However, pharmaceutical companies are thriving in these difficult times owing to the increasing demand for medication drugs across the globe. Likewise, the demand for these hedgehog pathway inhibitors is experiencing considerable growth as major pharmaceutical companies focus on R&D activities to develop new drugs and cater to the demand for OTC drugs across several stores and high prevalence of chronic target diseases across the globe. The market is, therefore, expected to showcase positive growth during the forecast period.
Hedgehog Pathway Inhibitors Market Segmentation Analysis
The basal cell carcinoma segment is expected to hold largest share in this market segment
Basal cell carcinoma (BCC) is the most common human cancer detected in Western populations and poses significant health expenditure. For instance, according to the American Cancer Society (ACS), an estimated 5.4 million people are diagnosed with squamous and basal cell skin cancer globally each year. Of these, 3.3 million people suffer from squamous cell skin cancer, and about 80% of the population suffers from basal cell carcinoma.
The vismodegib segment is expected to hold largest share in this market segment
Vismodegib is a drug for the treatment of basal-cell carcinoma. The approval of vismodegib on January 30, 2012, represents the first Hedgehog signaling pathway targeting agent to gain U.S. Food and Drug Administration approval which Genentech Inc discovered under a collaboration with Curis Inc. Vismodegib inhibits the Hedgehog (Hh) pathway, which is involved in tumorigenesis, thus providing a strong rationale for its use in the treatment of a variety of cancers.
The smoothened non-canonical pathway type of hedgehog inhibitors segment is expected to hold largest share in this market segment
Most basal cell carcinoma BCCs arise from the loss of patched homologue 1 (PTCH1) inhibition of the Smoothened (SMO) homologue. Smoothened is a protein that in humans is encoded by the SMO gene. Smoothened is a Class Frizzled (Class F) G protein-coupled receptor that is a component of the hedgehog signaling pathway and is conserved from flies to humans. It is the molecular target of the natural teratogen cyclopamine.
The oral route segment is expected to hold largest share in this market segment
Oral route for administration segment dominates the market due to the ease of application and efficient dose delivery to achieve desirable results, and oral drugs require no special skills and can easily carry around are some of the factors responsible for the market growth. For instance, In December 2018, Glasdegib, the first hedgehog pathway inhibitor drug, was approved for the treatment of acute myeloid leukemia (AML) patients. The drug was approved by the Food and Drug Administration (FDA) as once-daily oral medicine to be used in combination with low-dose cytarabine. Glasdegib is sold under the brand name Daurismo.
The retail pharmacies segment is expected to hold largest share in this market segment
The retail Pharmacies segment is expected to dominate during the forecast period. Hedgehog pathway inhibitors medications are easily, readily available in retail pharmacies as the generic medicine. Retail pharmacies offer convenient services, including home delivery of medicines and availability of all types of drugs and medicines. Moreover, consumer preference for easy availability of products due to busy lifestyles and hectic work schedules is anticipated to boost hedgehog pathway inhibitors market growth.
Hedgehog Pathway Inhibitors Market Geographical Share
North America region holds the largest market share of global hedgehog pathway inhibitors market
North America served to dominate the global market during the forecast period. High prevalence of basal cell carcinoma & acute myeloid leukemia and new product approvals are anticipated to drive the hedgehog pathway inhibitors market in the region during the forecast period. according to the American Cancer Society (ACS), an estimated 5.4 million people are diagnosed with squamous and basal cell skin cancer globally each year. For instance, Pellepharm has introduced Saridegib (Patidegib), a hedgehog pathway inhibitor. It is used as a topical treatment measure for patients with Gorlin Syndrome and Basal Cell Carcinomas (BCCs).
Hedgehog Pathway Inhibitors Market Companies and Competitive Landscape
The global hedgehog pathway inhibitors market is highly competitive with presence of global companies. Some of the key players which are contributing to the growth of the market include Pfizer Inc., F. Hoffmann-La Roche AG, Sun Pharmaceutical Industries Limited, Infinity Pharmaceuticals, Max Biopharma Inc, PellePharm Inc., Takeda Pharmaceutical Company Ltd, Mayne Pharma Group Limited, and Bristol-Myers Squibb Company, Novartis. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market globally. For instance, Mayne Pharma Group Limited took control of SUBA-itraconazole BCCNS program from HedgePath Pharmaceuticals, Inc.
Hedgehog pathway inhibitors Market Key Companies to Watch
Sun Pharmaceutical Industries Limited
Company Overview: Sun Pharmaceutical Industries Limited is an Indian multinational pharmaceutical company founded in 1983, headquartered in Mumbai, Maharashtra, that manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients primarily in India and the United States. Sun Pharmaceutical Industries Ltd. (Sun Pharma) is the fourth largest specialty generic pharmaceutical company in the world with global revenues of over US$ 4.5 billion.
Product Portfolio: The company offers formulations in various therapeutic areas, such as cardiology, psychiatry, neurology, gastroenterology and diabetology. It also provides APIs such as warfarin, carbamazepine, etodolac, and clorazepate, as well as anti-cancers, steroids, peptides, sex hormones, and controlled substances.
Key Developments: In 2016, Sun Pharmaceutical Industries Ltd. acquired Novartis pipeline product Odomzo (Sonidegib).
Why Purchase the Report?
- Visualize the composition of the hedgehog pathway inhibitors market segmentation by product type, route of administration, application, pathway type and region highlighting the key commercial assets and players.
- Identify commercial opportunities hedgehog pathway inhibitors market by analyzing trends and co-development deals.
- Excel data sheet with thousands of data points of hedgehog pathway inhibitors market - level 4/5 segmentation.
- PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
- Product mapping in excel for the key product of all major market players
The global hedgehog pathway inhibitors market report would provide an access to an approx. 77 market data table, 75 figures and 200 pages.
Target Audience
- Service Providers/ Buyers
- Industry Investors/Investment Bankers
- Education & Research Institutes
- Research Professionals
- Emerging Companies
- Manufacturers
